camrelizumab
mAbexperimentalCOVID-19
Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. PD-1 is programmed cell death protein 1. — Wikipedia
Clinical trial activity
508 trials · 94 clinical orgs · 0 marketing orgs
Phase 1
78
Phase 2
417
Phase 3
73
Phase 4
2
Earliest trial started Sep 1, 2015 (NCT02492789)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma of Lung · Phase 2
- Adrenal Gland Neoplasms · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Albumin-Bound Paclitaxel · Phase 2
- Allergy and Immunology · Phase 1
- Angiogenesis Modulating Agents · Phase 2
- Apoptosis · Phase 2
- Artificial Intelligence · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Biomarkers · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Bronchial Neoplasms · Phase 3
- Capecitabine · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Bronchogenic · Phase 3
- Carcinoma, Hepatocellular · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Carcinosarcoma · Phase 2
- Chemoembolization, Therapeutic · Phase 3
- Chemoradiotherapy · Phase 2/Phase 3
- Cholangiocarcinoma · Phase 2
- Chordoma · Phase 2
- Cisplatin · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- COVID-19 · Phase 1
- Death · Phase 1
- Dendritic Cells · Phase 2
- Digestive System Diseases · Phase 2
- Digestive System Neoplasms · Phase 2
- Disease-Free Survival · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drugs, Investigational · Phase 4
- Drug Therapy · Phase 3
- Electroconvulsive Therapy · Phase 2
- Endometrial Neoplasms · Phase 2
- Endostatins · Phase 2
- Epstein-Barr Virus Infections · Phase 2/Phase 3
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 2
- Fertility Preservation · Phase 2
- Gallbladder Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- General Surgery · Phase 3
- Genes, erbB-1 · Phase 2
- Genes, p53 · Phase 1
- Gestational Trophoblastic Disease · Phase 2
- Glioblastoma · Phase 2
- Granulocyte Colony-Stimulating Factor · Phase 2
- Head and Neck Neoplasms · Phase 2
- Herpesvirus 4, Human · Phase 2
- Hodgkin Disease · Phase 3
- Hyperbaric Oxygenation · Phase 1
- Hypopharyngeal Neoplasms · Phase 2
- Immune Checkpoint Inhibitors · Phase 3
- Immunotherapy · Phase 3
- Induction Chemotherapy · Phase 2
- Intestinal Neoplasms · Phase 2
- Killer Cells, Natural · Phase 2
- Lapatinib · Phase 3
- Leukemia, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Liposarcoma · Phase 2
- Liver Neoplasms · Phase 2
- Liver Transplantation · Phase 1/Phase 2
- Lung Diseases · Phase 3
- Lung Neoplasms · Phase 4
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Anaplastic · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Maintenance Chemotherapy · Phase 2
- Melanoma · Phase 3
- Microsatellite Instability · Phase 2
- Molecular Targeted Therapy · Phase 2
- Mouth Neoplasms · Phase 1
- Mutation · Phase 2
- Myelodysplastic Syndromes · Phase 1
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 3
- Neoadjuvant Therapy · Phase 2/Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neoplasms by Site · Phase 3
- Neoplasms, Connective and Soft Tissue · Phase 2
- Oncolytic Virotherapy · Phase 2
- Osteosarcoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Paranasal Sinus Neoplasms · Phase 2
- Pathology · Phase 2
- Pharmacokinetics · Phase 1/Phase 2
- Pleural Effusion, Malignant · Phase 1/Phase 2
- Progression-Free Survival · Phase 2
- Proto-Oncogene Proteins B-raf · Phase 1
- Radiotherapy · Phase 3
- ras GTPase-Activating Proteins · Phase 1
- ras Proteins · Phase 1
- Receptor, EphA2 · Phase 1
- Receptors, Vascular Endothelial Growth Factor · Phase 2
- Rectal Neoplasms · Phase 3
- Respiratory Tract Diseases · Phase 3
- Respiratory Tract Neoplasms · Phase 3
- Sarcoma · Phase 2
- Sezary Syndrome · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Stomach Diseases · Phase 2
- Stomach Neoplasms · Phase 3
- Survival · Phase 2
- Temozolomide · Phase 2
- Thoracic Neoplasms · Phase 3
- Thrombosis · Phase 2
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 3
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
- Vinorelbine · Phase 2
Mechanism of action
- Programmed cell death protein 1ANTAGONIST
PDCD1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCamrelizumab ↗
- ChEMBLCHEMBL4297715 ↗
Also known as
- incshr01210
- shr-1210
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07191977 | Phase 2 | Jan 31, 2026 | Sichuan University |
| NCT07113275 | Phase 3 | Jan 1, 2026 | Huazhong University of Science and Technology |
| NCT07309419 | Phase 2/Phase 3 (Phase 3) | Dec 22, 2025 | Fudan University |
| NCT07236528 | Phase 2 | Nov 30, 2025 | Nanjing University |
| NCT07143292 | Phase 2 | Nov 30, 2025 | Sun Yat-Sen University |
| NCT07238881 | Phase 2 | Nov 5, 2025 | Sun Yat-Sen University |
| NCT07312578 | Phase 2 | Nov 1, 2025 | Peking University |
| NCT07267806 | Phase 3 | Oct 31, 2025 | Sun Yat-Sen University |
| NCT07161791 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2025 | Harbin Medical University |
| NCT07167160 | Phase 2 | Sep 1, 2025 | Zhejiang University |
| NCT07107217 | Phase 2 | Aug 31, 2025 | Blokhin's Russian Cancer Research Center |
| NCT07159217 | Phase 2 | Aug 30, 2025 | Chinese Academy of Medical Sciences |
| NCT07105748 | Phase 2 | Aug 15, 2025 | Fudan University |
| NCT07100392 | Phase 2 | Aug 14, 2025 | Fudan University |
| NCT07067450 | N/A | Jul 20, 2025 | Sichuan University |
| NCT07057089 | Phase 2 | Jul 1, 2025 | Hebei University |
| NCT07059949 | Phase 2 | Jun 30, 2025 | Huazhong University of Science and Technology |
| NCT07026149 | Phase 2 | Jun 8, 2025 | Jiao Tong University |
| NCT06869226 | Phase 2 | Apr 30, 2025 | Peking University |
| NCT06849492 | Phase 2 | Apr 1, 2025 | Fudan University |
Showing 20 of 508 trials
Page 1 / 26
Organizations
Research & Development (94)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 123 | 54 | 4 | 2016 |
| Sun Yat-Sen University | Academic/Hospital | 77 | 66 | 4 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 62 | 50 | 4 | 2017 |
| Fudan University | Academic/Hospital | 57 | 54 | 5 | 2018 |
| Jiao Tong University | Academic/Hospital | 32 | 26 | 4 | 2018 |
| Huazhong University of Science and Technology | Academic/Hospital | 25 | 22 | 4 | 2018 |
| Peking University | Academic/Hospital | 25 | 24 | 3 | 2018 |
| People's Liberation Army of China | Government | 22 | 17 | 4 | 2016 |
| Sichuan University | Academic/Hospital | 19 | 12 | 4 | 2019 |
| Tianjin Medical University | Academic/Hospital | 19 | 15 | 3 | 2017 |
| Henan Medical University | Academic/Hospital | 18 | 18 | 3 | 2019 |
| Zhejiang University | Academic/Hospital | 17 | 9 | 3 | 2019 |
| Capital Medical University | Academic/Hospital | 15 | 11 | 3 | 2018 |
| Zhengzhou University | Academic/Hospital | 15 | 13 | 3 | 2019 |
| Fujian Medical University | Academic/Hospital | 12 | 12 | 3 | 2019 |
| Central South University | Academic/Hospital | 10 | 5 | 2 | 2020 |
| Guangzhou Medical University | Academic/Hospital | 9 | 5 | 3 | 2019 |
| Shandong University | Academic/Hospital | 9 | 6 | 3 | 2018 |
| Xiamen University | Academic/Hospital | 9 | 5 | 2 | 2019 |
| Harbin Medical University | Academic/Hospital | 8 | 8 | 2 | 2018 |
94 organizations
Page 1 / 5